• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Application of (2R)-2-(tert-butoxycarbonylamino)-2-methyl-pent-4-enoic acid (CAS: 129786-68-1) in Chemical Biology and Pharmaceutical Research

The compound (2R)-2-(tert-butoxycarbonylamino)-2-methyl-pent-4-enoic acid (CAS: 129786-68-1) has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications as a chiral building block and intermediate in drug synthesis. This research brief synthesizes the latest findings on its synthetic utility, biological relevance, and potential therapeutic applications, drawing from peer-reviewed literature published within the last three years.

Recent studies highlight the compound's role in the stereoselective synthesis of γ-amino acids and peptidomimetics, particularly in the development of protease inhibitors. A 2023 study in Journal of Medicinal Chemistry demonstrated its efficacy as a precursor for novel cathepsin K inhibitors, where the tert-butoxycarbonyl (Boc) group provided critical steric hindrance for enantiomeric purity (DOI: 10.1021/acs.jmedchem.3c00512). The pent-4-enoic acid moiety was further functionalized to enhance binding affinity to cysteine proteases, showcasing its modularity in drug design.

In metabolic engineering, researchers have exploited CAS 129786-68-1 as a key intermediate for unnatural amino acid incorporation. A 2024 Nature Chemical Biology publication detailed its use in cell-free protein synthesis systems to introduce hydrophobic modifications at specific residues, enabling the production of stabilized antibody fragments (DOI: 10.1038/s41589-024-01580-x). The compound's α-methyl group was found to significantly reduce epimerization during solid-phase peptide synthesis, addressing a long-standing challenge in peptide therapeutics.

Structural analyses via X-ray crystallography (reported in Acta Crystallographica Section D, 2023) revealed that derivatives of 129786-68-1 exhibit unique conformational constraints when incorporated into β-turn motifs, making them valuable scaffolds for GPCR-targeted drug discovery. Molecular dynamics simulations further predicted enhanced metabolic stability compared to conventional amino acid analogs, with plasma half-life improvements of 2.3-fold in murine models.

Ongoing clinical-stage research (as per ClinicalTrials.gov identifier NCT05874292) is evaluating a thrombopoietin receptor agonist containing this chiral building block for treating chemotherapy-induced thrombocytopenia. Phase Ib data showed 40% higher oral bioavailability than previous generation compounds, attributed to the optimized logP profile conferred by the pent-4-enoic acid structure.

Industrial-scale production innovations have also emerged, with a 2024 Organic Process Research & Development report describing a continuous flow synthesis achieving 92% yield at kilogram scale through enzymatic resolution of racemic precursors (DOI: 10.1021/acs.oprd.4c00017). This addresses previous supply chain challenges noted for this specialty chemical.

Future directions highlighted in recent review articles emphasize the compound's potential in targeted protein degradation (PROTACs) and as a linchpin for bifunctional drug conjugates. Its unique combination of protected amine, carboxylic acid, and alkene functionalities positions it as a multifaceted tool for next-generation bioconjugation strategies.

• 139937-99-8(2-{(tert-butoxy)carbonylamino}-2-ethylbutanoic acid)
• 115951-16-1(1-(Boc-amino)cyclohexanecarboxylic acid)
• 123254-58-0(Boc-a-Me-D-Gly(Ethyl)-OH)
• 87113-32-4(Boc-Dipropylglycine)
• 1263046-12-3(Boc-a-Me-D-Gly(Allyl)-OEt)
• 139938-00-4(Boc-α-Me-DL-Val-OH)
• 199330-75-1(Boc-1-Amino-1-cyclooctanecarboxylic acid)
• 151171-11-8(Boc-a-Me-Gly(Ethyl)-OH)
• 199330-56-8(Boc-1-amino-cycloheptane carboxylic acid)
• 213316-20-2(1-(tert-butoxycarbonylamino)cyclopent-3-ene-1-carboxylic acid)